Report : South America Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Application (Bakery and Confectionery, Dairy and Frozen Desserts, Beverages, Sauces; Dressings; and Condiments, RTC and RTE Products, Meat; Poultry and Seafood, and Others)
At 6.9% CAGR, the SAM Intravenous Immunoglobulin Market is speculated to be worth US$ 1,167.28 million by 2028, says Business Market Insights
According to Business Market Insights' research, the SAM intravenous immunoglobulin market was valued at US$ 783.22 million in 2022 and is expected to reach US$ 1,167.28 million by 2028, registering a CAGR of 6.9% from 2022 to 2028. Rising prevalence of immunodeficiency diseases and increasing geriatric population are the critical factors attributed to the market expansion.
Intravenous immunoglobulin (IVIG) is used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. IVIG is a standard therapy to treat most of the primary immunodeficiencies (PID). The rare genetic diseases can be chronic, weakening, and expensive to treat. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets; a situation referred to as thrombocytopenia. As per the Rare Diseases Organization, around 200,000 ITP cases are recorded across the region annually. Thus, increasing prevalence of immunodeficiency diseases drives the growth of the intravenous immunoglobulin market.
On the contrary, adverse effects of immunoglobulin therapy hurdles the growth of SAM intravenous immunoglobulin market.
Based on type, the SAM intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment held 29.1% market share in 2022, amassing US$ 227.58 million. It is projected to garner US$ 336.93 million by 2028 to expand at 6.8% CAGR during 2022-2028.
Based on application, the SAM intravenous immunoglobulin market is segmented hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment held 21.7% market share in 2022, amassing US$ 169.84 million. It is projected to garner US$ 261.34 million by 2028 to expand at 7.4% CAGR during 2022-2028.
Based on distribution channel, the SAM intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment held 55.9% market share in 2022, amassing US$ 437.70 million. It is projected to garner US$ 647.35 million by 2028 to expand at 6.7% CAGR during 2022-2028.
Based on end user, the SAM intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The beverages segment held 47.3% market share in 2022, amassing US$ 370.14 million. It is projected to garner US$ 543.19 million by 2028 to expand at 6.6% CAGR during 2022-2028.
Based on country, the SAM intravenous immunoglobulin market is segmented into Brazil, Argentina, and the Rest of SAM. Our regional analysis states that Brazil captured 47.3% market share in 2022. It was assessed at US$ 370.14 million in 2022 and is likely to hit US$ 543.19 million by 2028, exhibiting a CAGR of 6.6% during the forecast period.
Key players dominating the SAM intravenous immunoglobulin market are ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited among others.
In 2022, BPL and Atlantic Research Group entered into long-term collaboration. This agreement establishes ARG as BPL's preferred contract research organization (CRO) for conducting clinical research trials and providing supportive services for the company's global new product development programs. The agreement builds on BPL and ARG's previous successful collaboration on clinical trial programs. In 2021, Grifols began a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug
Based on the Grifols immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com